Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 single-blind two-part study of Veltassa in Chinese adults with hyperkalemia and chronic kidney disease on RAAS inhibitor therapy
CTR20212173Phase 3Completed
- Sponsor
- CSL Vifor
- Start
- Feb 2022
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
A Phase 3 trial of patiromer in hyperkalemia, sponsored by CSL Vifor. Started Feb 2022; status: completed.
02
Drugs
patiromer
03
Conditions
hyperkalemia
Beyond the preview
Go deeper on CTR20212173.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20212173.